Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
J Clin Oncol
    May 2018
  1. IYER G, Balar AV, Milowsky MI, Bochner BH, et al
    Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2018 May 9:JCO2017750158. doi: 10.1200/JCO.2017.75.0158.
    >> Share

    December 2017
  2. BOOTH CM, Karim S, Peng Y, Siemens DR, et al
    Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data.
    J Clin Oncol. 2017 Dec 13:JCO2017761759. doi: 10.1200/JCO.2017.76.1759.
    >> Share

    August 2017
  3. SHORE ND, Boorjian SA, Canter DJ, Ogan K, et al
    Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
    J Clin Oncol. 2017 Aug 23:JCO2017723064. doi: 10.1200/JCO.2017.72.3064.
    >> Share

    July 2017
  4. BALAR AV
    Immune Checkpoint Blockade in Metastatic Urothelial Cancer.
    J Clin Oncol. 2017;35:2109-2112.
    >> Share

    April 2017
  5. KULKARNI GS, Hermanns T, Wei Y, Bhindi B, et al
    Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Clin Oncol. 2017 Apr 14:JCO2016692327. doi: 10.1200/JCO.2016.69.2327.
    >> Share

    January 2017
  6. POWLES T, Huddart RA, Elliott T, Sarker SJ, et al
    Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Clin Oncol. 2017;35:48-55.
    >> Share

    July 2016
  7. DRAKE CG, Bivalacqua TJ, Hahn NM
    Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.
    J Clin Oncol. 2016 Jul 25. pii: JCO684696.
    >> Share

  8. PAL SK, Agarwal N, Boorjian SA, Hahn NM, et al
    National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    J Clin Oncol. 2016 Jul 25. pii: JCO681429.
    >> Share

  9. EAPEN LJ, MacRae RM
    Management Considerations After Cystectomy for Bladder Cancer.
    J Clin Oncol. 2016 Jul 18. pii: JCO679423.
    >> Share

  10. HU YW
    Real-World Role of Adjuvant Chemotherapy in Bladder Cancer.
    J Clin Oncol. 2016 Jul 11. pii: JCO675884.
    >> Share

  11. RUGGERI EM, Fabbri MA, Nelli F
    Should We Use Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer After Radical Cystectomy?
    J Clin Oncol. 2016 Jul 11. pii: JCO675132.
    >> Share

    June 2016
  12. GALSKY MD, Stensland K, Sfakianos JP, Mehrazin R, et al
    Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.
    J Clin Oncol. 2016 Jun 6. pii: JCO675033.
    >> Share

  13. MASSARD C, Gordon MS, Sharma S, Rafii S, et al
    Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    J Clin Oncol. 2016 Jun 6. pii: JCO679761.
    >> Share

    March 2016
  14. MILOWSKY MI, Rumble RB, Booth CM, Gilligan T, et al
    Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
    J Clin Oncol. 2016 Mar 21. pii: JCO659797.
    >> Share

    January 2016
  15. KAMAT AM, Sylvester RJ, Bohle A, Palou J, et al
    Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
    J Clin Oncol. 2016 Jan 25. pii: JCO644070.
    >> Share

  16. KUSHI LH, Quinn VP, Ghai NR, Roh JM, et al
    Identifying lifestyle and genetic factors to prevent recurrence of non-muscle invasive bladder cancer in a prospective cohort study at Kaiser Permanente (the Be-Well study).
    J Clin Oncol. 2016;34.
    >> Share

  17. DANFORTH KN, Kwan ML, Bulkley JE, O'Keeffe-Rosetti MC, et al
    Recovery challenges faced by bladder cancer survivors after recent cystectomy and urinary diversion.
    J Clin Oncol. 2016;34.
    >> Share

  18. GALSKY MD, Stensland KD, Moshier E, Sfakianos JP, et al
    Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
    J Clin Oncol. 2016 Jan 19. pii: JCO641076.
    >> Share

  19. SONPAVDE G, Gordetsky JB, Lockhart ME, Nix JW, et al
    Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?
    J Clin Oncol. 2016 Jan 19. pii: JCO654442.
    >> Share

  20. PAL SK, Agarwal N, Grivas P, Choueiri T, et al
    Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence.
    J Clin Oncol. 2016 Jan 19. pii: JCO654368.
    >> Share

    August 2015
  21. MARTIN-DOYLE W, Orsola A, Bellmunt J
    Reply to K. Lu.
    J Clin Oncol. 2015;33:2716-7.
    >> Share

    July 2015
  22. LU K
    Depth of Invasion in High-Grade T1 Bladder Cancer: Added Value In Timely Cystectomy?
    J Clin Oncol. 2015 Jul 20. pii: JCO.2015.62.2712.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016